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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer arising in the 
upper aerodigestive tract. It is an epithelial tumor most commonly affecting the oral cavity, 
hypopharynx, and larynx. HNSCC is the fifth most common cancer worldwide with 
approximately 900,000 cases yearly worldwide. In the United States, there were 
approximately 36,000 cases in 2010 and 8,000 deaths. Men are at significantly greater risk 
with tobacco and alcohol consumption the most important etiologic risk factors.  
The main treatment modality for HNSCC has traditionally been surgery and postoperative 
radiotherapy. However, over the past 30 years, no significant change has been made in 
treatment strategy with minimal improvement in survival. Overall survival at five years 
ranges from 70-85% for patients presenting with early-stage disease (stage I and II) to 30-
40% for advanced-stage disease (stage III and IV). 
2. Pathogenesis of head and neck cancer 
Mutations in specific genes and alteration of their expression lead to neoplasia in the head 
and neck. The development of HNSCC is a multi-step process with sequential mutations in 
genes responsible for tumor surveillance. A microsatellite analysis of allelic alterations 
showed that with the accumulation of genetic mutations, one can follow the transformation 
of cells from simple squamous hyperplasia to severe dysplasia, and, ultimately, invasive 
squamous cell carcinoma. These changes include mutation of the p53 tumor suppressor, 
overexpression of epidermal growth factor receptor (EGFR), and inactivation of the cyclin 
dependent kinase inhibitor p16. Other changes such as Rb mutation, ras activation, cyclin D 
amplification, and myc overexpression are less frequent in HNSCC. There is also an 
alteration in those genes which control DNA repair, proliferation, immortalization, 
apoptosis, invasion, and angiogenesis in HNSCC. 
The p53 gene is believed to be the most frequently mutated tumor suppressor in human 
cancer. p53 has been implicated in the early pathogenesis of HNSCC, as it controls cell 
growth through regulation of the cell-cycle and apoptosis. The p53 null keratinocytes 
possessing an activated ras oncogene proliferate at a higher rate than those expressing the 
tumor suppressor.  
www.intechopen.com
 
Squamous Cell Carcinoma 
 
138 
In a study by Kashiwazaki et al in HNSCC, 79% of cancers and 36% of dysplastic lesions 
were shown to have p53 mutations. Hyperplastic lesions were negative for p53 mutations in 
this study. A higher incidence of p53 mutations have been detected in invasive carcinomas 
(75%) than in non-invasive cancers (35%). p53 mutations were not detected in normal 
mucosal cells. This study also detected sequential mutations of different exons which 
suggested accumulation of alterations during neoplastic transformation. The incidence of 
p53 mutations correlated with the degree of dysplasia with significantly higher numbers 
found in smokers. In agreement with these studies, dysplastic lesions in non-smokers 
infrequently contained p53 mutations. These results indicate that p53 mutation and 
inactivation is an early event in head and neck tumorigenesis. 
In addition to p53, alterations in the retinoblastoma (Rb) gene are involved in the 
pathogenesis of HNSCC. The Rb protein is also a tumor suppressor pathway. p16INK4A, a 
major target of the Rb pathway is inhibited through a variety of pathways including loss of 
heterozygosity (LOH) of chromosome 9p21, where it is located. LOH of 9p21 is seen in 80% 
of malignant lesions.  
In addition to the p53 and Rb genes, sphingosine kinase (SphK) has been implicated in 
HNSCC. SphK regulates levels of ceramide, sphingosine, and sphingosine-1-phosphate, 
influencing cells to enter proliferative states. SphK1, a SphK isozyme is upregulated in 
HNSCC with overexpression in recurrent and advanced stage tumors. Use of small 
molecular inhibitors or siRNA’s targeting SphK1 sensitizes cells both in in vitro and in vivo 
studies leads to radiation induced cell death. As a cell cycle regulator overexpressed in 
HNSCC patients, SphK1 plays a significant role in the pathogenesis of HNSCC.  
The Epidermal Growth Factor Receptor (EGFR) is of the most studied biomarkers in 
HNSCC. EFGR is a receptor tyrosine kinase that effects cell growth, angiogenesis, and 
invasion. The epidermal growth factor receptor gene encodes a transmembrane receptor for 
EGF and transforming growth factor (TGF)-ǂ. Ligand binding to the extracellular domain 
induces receptor dimerization and activation of the cytoplasmic tyrosine kinase. Many 
epithelial cancers including that of the head and neck overexpress EGFR, its ligands, or 
both. EGFR has been detected in the basal layer of normal oropharyngeal mucosa. All cells 
from dysplastic head and neck lesions stain for EGFR as do the majority of carcinomas. 
Almost all cells in poorly differentiated head and neck tumors were positive for the 
receptor. Amplification of the EGFR gene has been demonstrated in cultured cells and 
tissues.  
EGFR overexpression may result in constitutive activity of the kinase domain and 
consequently increase downstream signaling such as that of the mitogen activated protein 
kinase pathway. The tyrosine kinase activity of the receptor results in autophosphorylation 
and recruitment of a variety of intracellular signaling proteins containing Src homology 2 
(SH2) or phosphotyrosine binding (PTB) domains. This recruitment provides a means of 
assembling the complexes required for receptor signaling. Proteins such as Grb2 and Shc, 
which contain SH2 and SH3 domains, mediate interactions with signal transduction 
proteins linking EGFR with the ras/mitogen activated protein kinase (MAPK) pathway. Ras 
also interacts with many proteins such as raf and phosphatidylinositol 3-kinase (PI3-K) to 
simulate downstream effectors such as MEK and ERK. These MAPKs are translocated to the 
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nucleus where they activate a number of transcription factors which control cellular 
proliferation, migration, and differentiation. 
With devastating effects on communication, swallowing, and most importantly, survival, 
new biomarkers and targeted therapies are needed to improve detection, treatment, and 
survival. Potential targeted therapies may be found in factors that regulate angiogenesis. 
Angiogenesis plays an important role in both tumor growth and metastasis.  Tumors are 
unlikely to grow beyond 3mm without the growth of new vessels. Receptor tyrosine kinases 
(RTKs) have emerged as important molecules in the regulation of angiogenesis.  
Abnormal RTK expression is characteristic of most human cancers. There are three families 
of receptor tyrosine kinases and their ligands important in vascular development, including 
the vascular endothelial growth factor receptor (VEGF) family, the angiopoietin family, and 
the ephrins and the Eph receptors. Of the three receptor tyrosine kinase families above, 
VEGF is the most extensively studied. VEGF has been shown to be overexppressed in tumor 
compared to normal cells. VEGF overexpression is associated with a 1.88 fold increased risk 
of death and is also shown to be associated with lymph node metastasis. This chapter 
focuses on the expression of EphB4 and EphrinB2 in HNSCC and possible therapeutic 
applications to reduce tumor burden and improve survival. 
3. The Eph receptors and their ligands the ephrins 
The Eph receptors (erythropoietin-producing human hepatocellcular carcinoma) form the 
largest family of RTKs. In this group of proteins, there are 15 members divided into EphA 
and EphB classes. The EphA subclass is tethered to the cell membrane by glycosyl 
phosphatidylinositol, and the EphB subclass has a transmembrane domain that is followed 
by a short cytoplasmic region.  
Eph receptors have an extracellular domain composed of the ligand-binding globular 
domain, a cysteine rich region followed by a pair of fibronectin type III repeats. The 
cytoplasmic domain consists of a juxtamembrane region containing two conserved tyrosine 
residues, a protein tyrosine kinase domain, a sterile ǂ-motif (SAM), and a PDZ-domain 
binding motif.  
The ephrins (Eph family receptor interacting proteins) are the ligands for the Eph receptors, 
with 13 members, also divided into classes A and B. Class B Ephrins have a transmembrane 
domain and cytoplasmic region with five conserved tyrosine residues and a PDZ domain. 
EphrinB2 is the exclusive ligand for EphB4. EphB4 is normally expressed on venous 
endothelial cells while EphrinB2 on arterial endothelial cells. In contrast, the A class ligands 
have a glycosylphosphatidylinositol membrane anchor.  
Eph receptors are activated by binding of clustered, membrane attached ephrins indicating 
that contact between cells expressing the receptors and cells expressing the ligands is 
required for Eph activation. A corollary of this is that soluble ligands would act as inhibitors 
of Eph activation. Ligand binding to the Eph receptor autophosphorylates the 
juxtamembrane tyrosine residues to acquire full activation. Specificity of the ligand to its 
receptor is mediated by the N-terminal domain of the receptor. The interactions between the 
Eph receptors and their ligands form a bi-directional signaling pathway with forward Eph 
receptor signaling and reverse ephrin signaling (Figure 1).  
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Fig. 1. Bidirectional signaling between EphB4 and EphrinB2. 
P 
P 
P 
P 
PDZ binding motif 
SAM domain 
Juxtamembrane region 
Transmembrane region 
Fibronectin-type III repreats 
Globular domain 
Cysteine rich region 
PDZ binding motif 
Cytoplasmic tail 
Kinase domain 
Ephrin B2 
EphB4 
Artery 
Vein 
 
www.intechopen.com
 
The Role of EphB4 and EphrinB2 in Head and Neck Squamous Cell Carcinoma 
 
141 
When activated, EphB4 and EphrinB2 become phosphorylated, forming complexes with 
other proteins, and affect downstream signaling. Reverse signaling is initiated through 
recruitment of Src-family kinases followed by phosphorylation of ephrin B proteins. 
Evidence suggests that the Eph/ephrin interaction influences and is influenced in turn by 
other signaling pathways. The endothelial-specific receptor Tie-2 can directly phosphorylate 
ephrin cytoplasmic domains while EphrinB1 is phosphorylated by the PDGF receptor, and 
inhibits PDGF induced focus formation. Similarly, EphrinB2 inhibits VEGF signaling and 
the proliferation and migration of endothelial cells. The ephrins have also been shown to 
couple to GPCRs, such as the chemokine receptor CXCR4, via the PDZ linking proteins and 
a ternary complex involving the extracellular domains of EphrinB1, EphB2, and the 7-
transmembrane GPCR subunit of the NMDA glutamate receptor has also been 
demonstrated.  
The Eph receptor/ephrin system has been shown to play a role in several biologic processes. 
These processes include embryonic development, cell migration and aggregation, 
segmentation, pattern recognition, neural development, angiogenesis, vascular network 
development, and immune regulation. Recently, a role for these proteins has emerged in 
cancer.  
Several studies have demonstrated that the Eph receptor/ephrin system plays a role in 
tumorigenesis. Dodolet et al and Wimmer-Kleikamp et al have shown involvement of the 
Eph receptor/ephrin system in angiogenesis, invasion, and tumor metastasis. There is also 
evidence that elevated expression of the Eph/Ephrin system correlates with increased 
invasiveness in tumors including malignant melanoma, ovarian carcinoma, breast cancer, 
kidney carcinoma, neuroblastoma, and prostate cancer. More specifically, elevated EphB4 
expression has been shown in hematologic, breast, endometrial, prostate, bladder, ovarian, 
and colon cancers as well as malignant mesothelioma.  
EphB4 activation has been shown to increase proliferation and survival of microvascular 
endothelial cells through increased phosphatidylinositol 3-kinase activity and 
phosphorylation of mitogen-activated protein kinase (MAPK) and protein kinase B (Akt). 
EphB4’s involvement in cell migration and invasion is associated with EphB4 induction of 
MMP2 and MMP9, thus demonstrating a role for EphB4 in tumor metastasis.  
4. Expression of EphB4 and EphrinB2 in HNSCC 
As demonstrated in many other tumors, EphB4 is overexpressed in HNSCC. Through in situ 
hybridization, western blot analysis, and immunofluorescence of HNSCC tumor samples, 
EphB4 expression was found to be elevated in tumor tissue compared to normal adjacent 
tissue. In addition, EphB4 was overexpressed in metastatic lymph nodes (Figure 2). 
Furthermore, EphB4 overexpression correlated with advanced tumor stage (stage III or IV) 
and lymph node metastasis with stage III and IV tumors having 2.8 and 5.5-fold 
overexpression respectively compared to adjacent normal tissue.  
Lymph nodes positive with tumor had 7.8-fold higher expression compared to normal 
adjacent tissue. In contrast, in patients with early-stage disease (stage I or II), EphB4 
overexpression was 2.1-fold greater in tumor compared to adjacent normal tissue. Using  
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Fig. 2. EphB4 is expressed in HNSCC primary tissues and metastases. (a) Top panel: 
Immunofluorescence of representative fresh frozen sections of tumors (left and middle 
panels) or adjacent normal tissue (right panel) stained with EphB4-specific monoclonal 
antibody and visualized with FITC (green color). Sections were counter-stained with DAPI 
to identify cell nuclei. Bottom panel: Hematoxylin and Eosin (H&E) staining of the next 
serial section. Arrowhead in middle panel shows a vessel staining positive for EphB4. (b) 
Representative high power photomicrographs of tumor sections stained for EphB4 to 
document tumor cell membrane-specific expression. (c) In situ hybridization (ISH) of 
representative tumor sections with EphB4-specific antisense or sense probe. Arrows show 
positive signal for mRNA. H&E stain of the next section is shown in the right panel. Arrows 
indicate regions of the tumor. 
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quantitative PCR at the EphB4 gene locus, 30% of patients were found to have gene 
amplification of EphB4 with at least four copies of the gene locus. In a study of 42 patients 
with HNSCC, EphrinB2 expression was also analyzed with western blot analysis. EphrinB2 
was found to be overexpressed in HNSCC tumor samples with an average overexpression 
of 2.2-fold greater when compared to normal adjacent tissue. Therefore, both EphB4 and 
EphrinB2 have been shown to be overexpressed in HNSCC.  
5. HNSCC risk factors and EphB4 expression 
The two main risk factors for HNSCC are alcohol and smoking. Studies have shown that 
tobacco use can lead to a 20-fold increased risk of HNSCC. Tobacco related substances can 
alter the genes and growth factors associated with HNSCC and can affect the genomic 
stability and extracellular environment in HNSCC. The expression of EphB4 in the oral 
mucosa of smokers without HNSCC was analyzed and results showed no expression of 
EphB4. However, in patients with HNSCC, EphB4 expression in tumor specimens in 
nonsmokers was compared to that of patients with a smoking history. There was a 
significantly increased expression of EphB4 in tumor samples from patients with a smoking 
history compared to nonsmokers, with a 3.8-fold overexpression of EphB4 in smokers 
compared to a 2.1 fold overexpression in nonsmokers. Therefore, tobacco-related substances 
may induce signaling changes that increase and activate EphB4 leading to changes in 
angiogenesis and tumor growth.  
 
 
 
Fig. 3. Kaplan-Meier Curve for Overall Survival in Patients with Elevated Expression of 
EphB4 and EphrinB2. 
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In addition to smoking status, the effect of alcohol intake on EphB4 expression was also 
assessed in patients with HNSCC. Unlike with smoking status, EphB4 expression was not 
altered by a history of alcohol consumption. This is likely related to differing mechanisms of 
toxin induced carcinogenesis between alcohol and smoking.  
6. EphB4 and EphrinB2 expression and survival 
As increasing EphB4/EphrinB2 system expression is associated with advanced tumor stage 
and lymph node metastasis, the effect of EphB4 and EphrinB2 overexpression on survival 
was also studied. Patients who had high expression of EphB4 and EphrinB2 were compared 
to patients with low expression of EphB4 and EphrinB2. Those with high expression of 
EphB4 had a 5 year survival of 15% compared to 64% in patients with low EphB4 
expression. Patients with elevated EphrinB2 expression had a 5 year survival of 9% 
compared to 79% in patients with low EphrinB2 expression.  
In patients with elevated EphB4 and EphrinB2 expression, 5 year survival was 0% compared 
to 73% in patients with low EphB4 and low EphrinB2 expression (Figure 3). Therefore, 
elevated EphB4 and EphrinB2 expression is a significant predictor of poorer overall 
survival, even after adjusting for confounders including age, sex, race, stage, site of tumor, 
and mode of treatment. As all patients with high EphB4 and EphrinB2 expression died; this 
suggests a synergistic role between EphB4 and EphrinB2 in HNSCC.  
7. Inhibition of EphB4 and tumor cell survival 
EphB4 overexpression is associated with a worse overall survival in HNSCC; therefore, its 
inhibition in tumor cells is an important step to understanding possible therapeutic 
opportunities. Using small interfering RNA (siRNA) against the EphB4 sequence, which 
ablates EphB4 expression, results in a significant decrease in HNSCC tumor cells. In the 
presence of epidermal growth factor (EGF), which has been shown to induce EphB4 
expression, inhibition with siRNA against EphB4 also led to a decrease in tumor cells  
(Figure 4). The population of cells exposed to the siRNA against EphB4 was found to 
accumulate in the sub-G0 phase, suggestive of apoptosis. EphB4 was shown to provide a 
survival advantage to cells by inhibition of apoptotic pathways. Inhibition of EphB4 in a 
murine HNSCC model showed a reduction in tumor growth. Its knockdown leads to an 
activation of capase-8 and subsequent cell death by apoptosis. Therefore, EphB4 expression 
in HNSCC provides a survival advantage to tumors cells and is an important potential 
biomarker whose inhibition may improve survival. 
8. Therapeutic applications 
Tumor biomarkers provide an opportunity with which one can improve early detection of 
tumor, monitoring, and treatment, and ultimately improve survival. Recently, several new 
biomarkers have emerged and are currently being studied for their effectiveness in HNSCC 
detection, prognosis, and treatment. One such molecule is cetuximab, a monoclonal 
antibody against the epidermal growth factor receptor. It is one of the most successful 
targeted therapies in HNSCC with a phase III clinical trial showing cetuximab in 
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Fig. 4. Ablation of EphB4 in HNSCC cells lines results in reduction in cell numbers and 
inhibition of tumor cell migration/invasion. (a) Potent EphB4-specific siRNA chosen from 
their ability to block EphB4 was transfected at various concentrations into SCC-15 cells. A 
mutant siRNA (EphB4 siRNAΔ) with three base substitutions was used as negative control. 
Extracts of treated cells were analyzed by Western blotting to detect EphB4 and ǃ-actin 
(upper panel). SCC-15 cells were transfected with 100 nM EphB4 siRNA and EphB4 
expression analyzed at various time points (lower panel). (b) MTT cell number assays of 
EphB4-positive SCC cell lines (SCC-15 and -71) and an EphB4-negative cell line (SCC-4). Cell 
number was tested 48 hr following treatment with lipofectamine alone (Lipo), EphB4-
specific siRNA (EphB4 siRNA) or mutant siRNA (EphB4 siRNAΔ). Data shown is mean ± 
SEM of triplicate samples. (c) MTT cell number assays of SCC-15 cells following treatment 
with increasing doses of EGF and lipofectamine alone (Lipo), EphB4-specific siRNA (EphB4 
siRNA) or mutant siRNA (EphB4 siRNAΔ). Data shown is mean ± SEM of triplicate 
samples. 
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combination with radiotherapy provided an overall survival benefit of an additional 20 
months compared to radiation alone. Downstream EGFR signaling activates the MAPK 
pathway as well as the PI3-K/Akt pathway. Signaling through the PI3-K/Akt pathway 
ultimately leads to inhibition of the tumor suppressor gene p53. EGFR has been shown to 
regulate EphB4 expression (Figure 5). EGFR signaling through the Akt pathway induces 
EphB4. Inhibition of EGFR through antibodies such as cetuximab may also downregulate 
EphB4 through Akt. Potentially, some of the survival benefit of cetuximab is achieved 
through EphB4 inhibition.  
 
 
Fig. 5. Regulation of EphB4 expression by EGFR signaling pathway. (a) EGFR kinase 
inhibitor AG1478 was tested in SCC-15 for optimal dose (left upper panel) and time (left 
lower panel) for inhibition of EphB4 expression by Western blot of whole cell lysates. Equal 
loading of protein in each lane is shown by ǃ-actin levels. Inhibition of EGFR activation by 
EGF in the presence of AG1478 (1 µM) is shown in right panel. (b) Western blot analysis of 
SCC-15, -25, and -71 cell lines for regulation of EphB4, EGFR and EphrinB2 in response to 
AG1478. Serial stripping and probing for various proteins was performed from the same 
blot. 
Monoclonal antibodies to EphB4 have not been applied clinically as of yet, however, their 
development is crucial to improve survival in HNSCC. Xu et al have developed a 
humanized version of a mouse monoclonal antibody to EphB4 that binds the human EphB4 
receptor. Krasnoperov et al have also developed two anti-ephB4 monoclonal antibodies 
targeting different EphB4 domains. These antibodies have yet to be tested in humans. 
Bardelle el al have demonstrated a non-benxodioxole inhibitor of EphB4 that may have 
applications in vivo but is also yet to be studied further.  
In addition to the direct inhibition of the EphB4, several receptor tyrosine kinase inhibitors 
are being studied. These may also inhibit EphB4 function. Sunitinib, sorafenib, vandetanib, 
semaxanib, and foretinib are small molecule tyrosine kinase inhibitors currently being 
studied in phase II clinical trials. Machiels et al reviewed Sunitinib in a phase II clinical trial 
of 38 HNSCC patients in which it was given as a palliative treatment achieving a disease 
control rate of 50%. Due to several complications that occurred including bleeding, skin 
ulceration, and fistulas, they recommended further study of the drug to assess which 
patients would benefit. In recurrent/metastatic HNSCC and nasopharyngeal carcinoma, 
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Sorafenib’s effect was studied and a response rate of 3.7% was achieved. As a multikinase 
inhibitor, its effect cannot be attributed only to its anti-angiogenic activity. As a single agent, 
Semaxanib was also studied in HNSCC, but was discontinued due to several adverse affects 
and its difficulty with administration. Given the potential improvement in survival with 
EphB4 inhibition in HNSCC, new therapies targeting EphB4 are essential and further 
investigation is necessary.  
9. Conclusion 
Head and neck squamous cell carcinoma is the most common cancer of the head and neck 
with devastating effects on communication, swallowing, quality of life, and, most 
importantly, survival. The Eph receptor family and its ligands, the ephrins, specifically 
EphB4 and EphrinB2, have an important role in many physiologic processes including cell 
aggregation and migration, angiogenesis, and vascular network development.  
EphB4 and its sole ligand EphrinB2 are overexpressed in all HNSCC patients, with EphB4 
overexpression correlating with advanced stage disease and lymph node metastasis. In vivo, 
EphB4 has also been demonstrated to provide a survival advantage to tumor cells, and, its 
inhibition has been shown to decrease the survival of the HNSCC tumor cells. Furthermore, 
EphB4/EphrinB2 overexpression is associated with a significantly poorer overall survival. 
Given that EphB4 and EphrinB2 are overexpressed in HNSCC and that this is associated 
with worse overall survival, EphB4 and EphrinB2 are potentially useful biomarkers that 
may provide another target for HNSCC treatment. While there are several investigators 
examining the therapeutic role of EphB4 inhibition in cancer, there is still a great deal of 
progress to be made to apply EphB4 and EphrinB2 inhibition in head and neck squamous 
cell carcinoma treatment.  
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